A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma

Trial Profile

A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Copper-gluconate/disulfiram (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Cantex Pharmaceuticals
  • Most Recent Events

    • 31 Jul 2018 Planned End Date changed from 30 Jun 2018 to 30 Nov 2018.
    • 31 Jul 2018 Planned primary completion date changed from 30 Apr 2018 to 30 Sep 2018.
    • 31 Jul 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top